Previous Section
Clinical Trials
1. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
- Author
- Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H; Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
- Institution
- Service d'Hematologie, Centre Hospitalier Universitaire, Lille, France. t-facon@chru-lille.fr
- Journal
- Lancet. 2007 Oct 6;370(9594):1209-18.
- Abstract URL
- Click here to view abstract
2. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
- Author
- Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS;
- Institution
- Institute for Myeloma and Bone Cancer Research and Oncotherapeutics Inc, West Hollywood, CA 90069, USA. jberenson@imbcr.org
- Journal
- Clin Cancer Res. 2007 Mar 15;13(6):1762-8.
- Abstract URL
- Click here to view abstract
3. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
- Author
- Zangari M; van Rhee F; Anaissie E; Pineda-Roman M; Haessler J; Crowley J; Barlogie B;
- Institution
- Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Journal
- Br J Haematol. 2008 May;141(4):433-44. Epub 2008 Mar 26.
- Abstract URL
- Click here to view abstract
4. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
- Author
- Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD;
- Institution
- Department of Haematology, St. Bartholomew's Hospital, London, UK.
- Journal
- Br J Haematol. 2008 May;141(4):512-6. Epub 2008 Mar 26.
- Abstract URL
- Click here to view abstract
5. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
- Author
- Rajkumar SV; Rosinol L; Hussein M; Catalano J; Jedrzejczak W; Lucy L; Olesnyckyj M; Yu Z; Knight R; Zeldis JB; Blade J;
- Institution
- Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu
- Journal
- J Clin Oncol. 2008 May 1;26(13):2171-7. Epub 2008 Mar 24.
- Abstract URL
- Click here to view abstract
6. Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile.
- Author
- Hattori Y; Okamoto S; Shimada N; Kakimoto T; Morita K; Tanigawara Y; Ikeda Y;
- Institution
- Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shimanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. yhattori@sc.itc.keio.ac.jp
- Journal
- Cancer Sci. 2008 Jun;99(6):1243-50. Epub 2008 Mar 31.
- Abstract URL
- Click here to view abstract
7. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
- Author
- Mateo G; Montalban MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutierrez N; Rosinol L; Montejano L; Blade J; Martinez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF;
- Institution
- Hospital Universitario de Salamanca, Salamanca, Spain.
- Journal
- J Clin Oncol. 2008 Jun 1;26(16):2737-44. Epub 2008 Apr 28.
- Abstract URL
- Click here to view abstract
8. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
- Author
- Richardson PG; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Miguel JS; Blade J; Boccadoro M; Cavenagh J; Alsina M; Rajkumar SV; Lacy M; Jakubowiak A; Dalton W; Boral A; Esseltine DL; Schenkein D; Anderson KC;
- Institution
- Dana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
- Journal
- Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9.
- Abstract URL
- Click here to view abstract
9. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
- Author
- Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T;
- Institution
- Department of Hematology and Oncology, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. yoshioga@is.icc.u-tokai.ac.jp
- Journal
- Cancer Sci. 2008 Jan;99(1):140-4. Epub 2007 Oct 27.
- Abstract URL
- Click here to view abstract
10. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
- Author
- Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
- Institution
- Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden. henrik.mellqvist@vgregion.se
- Journal
- Cancer. 2008 Jan 1;112(1):129-35.
- Abstract URL
- Click here to view abstract
